(DLB) Dolby Laboratories - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US25659T1079
Audio Codecs, Video Codecs, Cinema Systems, Immersive Media
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.83% |
| Yield on Cost 5y | 1.53% |
| Yield CAGR 5y | 10.36% |
| Payout Consistency | 87.0% |
| Payout Ratio | 34.2% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 22.0% |
| Value at Risk 5%th | 32.2% |
| Relative Tail Risk | -11.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.67 |
| Alpha | -31.33 |
| CAGR/Max DD | -0.14 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.353 |
| Beta | 0.809 |
| Beta Downside | 0.765 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.97% |
| Mean DD | 11.12% |
| Median DD | 10.77% |
Description: DLB Dolby Laboratories January 07, 2026
Dolby Laboratories (NYSE:DLB) designs and manufactures audio, imaging, and accessibility hardware and software for TV, broadcast, and live-entertainment markets worldwide, licensing its core codecs (AAC, HE-AAC, Dolby Atmos, Dolby Vision, DD+, AC-4, HEVC) to device makers, content creators, and service providers.
The firm’s product portfolio spans premium cinema solutions (Dolby Cinemas), a cloud-based developer platform (Dolby.io) for real-time immersive experiences, and a suite of digital cinema servers, processors, amplifiers, and loudspeakers that support theatrical, broadcast, and home-entertainment distribution.
Recent KPI highlights: FY 2024 revenue grew ~9% YoY to $1.78 billion, with the SaaS segment (Dolby.io) posting a 35% compound annual growth rate over the past three years, and operating margin expanding to 21% as licensing revenue benefits from the global shift toward streaming and immersive content. Key sector drivers include rising consumer demand for high-dynamic-range video and object-based audio in OTT platforms, and the continued rollout of 5G, which accelerates adoption of low-latency, cloud-native media workflows.
For a deeper quantitative look at Dolby’s valuation dynamics, you might explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (255.0m TTM) > 0 and > 6% of Revenue (6% = 80.9m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 3.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.45% (prev 60.97%; Δ 9.48pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 472.2m > Net Income 255.0m (YES >=105%, WARN >=100%) |
| Net Debt (-663.0m) to EBITDA (387.8m) ratio: -1.71 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (96.8m) change vs 12m ago 0.26% (target <= -2.0% for YES) |
| Gross Margin 88.13% (prev 88.97%; Δ -0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.44% (prev 40.69%; Δ 1.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -20.24 (EBITDA TTM 387.8m / Interest Expense TTM -14.3m) >= 6 (WARN >= 3) |
Altman Z'' 9.83
| (A) 0.29 = (Total Current Assets 1.39b - Total Current Liabilities 437.8m) / Total Assets 3.23b |
| (B) 0.82 = Retained Earnings (Balance) 2.63b / Total Assets 3.23b |
| warn (B) unusual magnitude: 0.82 — check mapping/units |
| (C) 0.09 = EBIT TTM 289.2m / Avg Total Assets 3.18b |
| (D) 4.40 = Book Value of Equity 2.62b / Total Liabilities 595.8m |
| Total Rating: 9.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.48
| 1. Piotroski 5.0pt |
| 2. FCF Yield 7.95% |
| 3. FCF Margin 31.89% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -1.71 |
| 6. ROIC - WACC (= 4.53)% |
| 7. RoE 9.90% |
| 8. Rev. Trend 6.08% |
| 9. EPS Trend -18.73% |
What is the price of DLB shares?
As of January 13, 2026, the stock is trading at USD 64.42 with a total of 452,608 shares traded.
Over the past week, the price has changed by +0.91%, over one month by -4.62%, over three months by -5.78% and over the past year by -16.59%.
Over the past week, the price has changed by +0.91%, over one month by -4.62%, over three months by -5.78% and over the past year by -16.59%.
Is DLB a buy, sell or hold?
Dolby Laboratories has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy DLB.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.5 | 40.5% |
| Analysts Target Price | 90.5 | 40.5% |
| ValueRay Target Price | 63.1 | -2.1% |
DLB Fundamental Data Overview January 10, 2026
P/E Trailing = 24.2824
P/E Forward = 15.3139
P/S = 4.5037
P/B = 2.3407
P/EG = 2.0755
Beta = 0.876
Revenue TTM = 1.35b USD
EBIT TTM = 289.2m USD
EBITDA TTM = 387.8m USD
Long Term Debt = 38.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 38.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -663.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.41b USD (6.08b + Debt 38.9m - CCE 701.9m)
Interest Coverage Ratio = -20.24 (Ebit TTM 289.2m / Interest Expense TTM -14.3m)
EV/FCF = 12.58x (Enterprise Value 5.41b / FCF TTM 430.3m)
FCF Yield = 7.95% (FCF TTM 430.3m / Enterprise Value 5.41b)
FCF Margin = 31.89% (FCF TTM 430.3m / Revenue TTM 1.35b)
Net Margin = 18.90% (Net Income TTM 255.0m / Revenue TTM 1.35b)
Gross Margin = 88.13% ((Revenue TTM 1.35b - Cost of Revenue TTM 160.1m) / Revenue TTM)
Gross Margin QoQ = 87.13% (prev 86.06%)
Tobins Q-Ratio = 1.68 (Enterprise Value 5.41b / Total Assets 3.23b)
Interest Expense / Debt = 0.29% (Interest Expense 114.0k / Debt 38.9m)
Taxrate = -19.17% (negative due to tax credits) (-7.99m / 41.7m)
NOPAT = 344.6m (EBIT 289.2m * (1 - -19.17%)) [negative tax rate / tax credits]
Current Ratio = 3.17 (Total Current Assets 1.39b / Total Current Liabilities 437.8m)
Debt / Equity = 0.01 (Debt 38.9m / totalStockholderEquity, last quarter 2.62b)
Debt / EBITDA = -1.71 (Net Debt -663.0m / EBITDA 387.8m)
Debt / FCF = -1.54 (Net Debt -663.0m / FCF TTM 430.3m)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.02% (Net Income 255.0m / Total Assets 3.23b)
RoE = 9.90% (Net Income TTM 255.0m / Total Stockholder Equity 2.58b)
RoCE = 11.05% (EBIT 289.2m / Capital Employed (Equity 2.58b + L.T.Debt 38.9m))
RoIC = 13.37% (NOPAT 344.6m / Invested Capital 2.58b)
WACC = 8.85% (E(6.08b)/V(6.11b) * Re(8.90%) + D(38.9m)/V(6.11b) * Rd(0.29%) * (1-Tc(-0.19)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 75.89% ; FCFF base≈377.1m ; Y1≈397.4m ; Y5≈467.3m
Fair Price DCF = 126.1 (EV 6.98b - Net Debt -663.0m = Equity 7.64b / Shares 60.6m; r=8.85% [WACC]; 5y FCF grow 5.89% → 2.90% )
EPS Correlation: -18.73 | EPS CAGR: -48.03% | SUE: -4.0 | # QB: 0
Revenue Correlation: 6.08 | Revenue CAGR: -3.55% | SUE: 0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.36 | Chg30d=+0.050 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-09-30): EPS=4.26 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+0.5% | Growth Revenue=+4.8%
EPS next Year (2027-09-30): EPS=4.60 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+8.0% | Growth Revenue=+3.2%
P/E Forward = 15.3139
P/S = 4.5037
P/B = 2.3407
P/EG = 2.0755
Beta = 0.876
Revenue TTM = 1.35b USD
EBIT TTM = 289.2m USD
EBITDA TTM = 387.8m USD
Long Term Debt = 38.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 38.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -663.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.41b USD (6.08b + Debt 38.9m - CCE 701.9m)
Interest Coverage Ratio = -20.24 (Ebit TTM 289.2m / Interest Expense TTM -14.3m)
EV/FCF = 12.58x (Enterprise Value 5.41b / FCF TTM 430.3m)
FCF Yield = 7.95% (FCF TTM 430.3m / Enterprise Value 5.41b)
FCF Margin = 31.89% (FCF TTM 430.3m / Revenue TTM 1.35b)
Net Margin = 18.90% (Net Income TTM 255.0m / Revenue TTM 1.35b)
Gross Margin = 88.13% ((Revenue TTM 1.35b - Cost of Revenue TTM 160.1m) / Revenue TTM)
Gross Margin QoQ = 87.13% (prev 86.06%)
Tobins Q-Ratio = 1.68 (Enterprise Value 5.41b / Total Assets 3.23b)
Interest Expense / Debt = 0.29% (Interest Expense 114.0k / Debt 38.9m)
Taxrate = -19.17% (negative due to tax credits) (-7.99m / 41.7m)
NOPAT = 344.6m (EBIT 289.2m * (1 - -19.17%)) [negative tax rate / tax credits]
Current Ratio = 3.17 (Total Current Assets 1.39b / Total Current Liabilities 437.8m)
Debt / Equity = 0.01 (Debt 38.9m / totalStockholderEquity, last quarter 2.62b)
Debt / EBITDA = -1.71 (Net Debt -663.0m / EBITDA 387.8m)
Debt / FCF = -1.54 (Net Debt -663.0m / FCF TTM 430.3m)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.02% (Net Income 255.0m / Total Assets 3.23b)
RoE = 9.90% (Net Income TTM 255.0m / Total Stockholder Equity 2.58b)
RoCE = 11.05% (EBIT 289.2m / Capital Employed (Equity 2.58b + L.T.Debt 38.9m))
RoIC = 13.37% (NOPAT 344.6m / Invested Capital 2.58b)
WACC = 8.85% (E(6.08b)/V(6.11b) * Re(8.90%) + D(38.9m)/V(6.11b) * Rd(0.29%) * (1-Tc(-0.19)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 75.89% ; FCFF base≈377.1m ; Y1≈397.4m ; Y5≈467.3m
Fair Price DCF = 126.1 (EV 6.98b - Net Debt -663.0m = Equity 7.64b / Shares 60.6m; r=8.85% [WACC]; 5y FCF grow 5.89% → 2.90% )
EPS Correlation: -18.73 | EPS CAGR: -48.03% | SUE: -4.0 | # QB: 0
Revenue Correlation: 6.08 | Revenue CAGR: -3.55% | SUE: 0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.36 | Chg30d=+0.050 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-09-30): EPS=4.26 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+0.5% | Growth Revenue=+4.8%
EPS next Year (2027-09-30): EPS=4.60 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+8.0% | Growth Revenue=+3.2%
Additional Sources for DLB Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle